title: Apheresis techniques in lymphokine-activated killer cell production.
abstract: Adoptive transfer of autologous lymphokine-activated killer cells (LAK) in conjunction with recombinant interleukin-2 (rIL-2) has been reported to produce significant regression in metastatic disease in patients with advanced cancer. In an effort to confirm the results reported by the Surgery Branch of the National Cancer Institute, the same IL-2/LAK regimen was used in cancer patients at six extramural cancer centers. In this report we will review our experience with mononuclear cell removal from the blood of cancer patients using apheresis technology and extracorporeal handling of these cells to generate a selective, highly cytotoxic cell population.
authors.affiliation: Blood Transfusion Services, City of Hope National Medical Center, Duarte, CA 91010.
authors.forename: I
authors.initials: I
authors.lastname: Sniecinski
authors.forename: K
authors.initials: K
authors.lastname: Sentinella
authors.forename: K
authors.initials: K
authors.lastname: Margolin
authors.forename: B
authors.initials: B
authors.lastname: Mills
mesh_terms: D000328:Adult; D001781:Blood Component Removal / Q000379:methods*; D003110:Colonic Neoplasms / Q000628:therapy; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000494:pharmacology* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy; D007694:Killer Cells, Natural; D007937:Leukapheresis; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D008213:Lymphocyte Activation; D008297:Male; D008545:Melanoma / Q000628:therapy; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology; D012004:Rectal Neoplasms / Q000628:therapy
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins